Delays in diagnosis, variations in treatment for morphea

Delays in diagnosis, variations in treatment for morphea
Patients with localized scleroderma (morphea) often experience delay in diagnosis and variability in treatment that is based more on the specialty of the provider than disease characteristics, according to a study published in the November issue of the Journal of the American Academy of Dermatology.

(HealthDay)—Patients with localized scleroderma (morphea) often experience delay in diagnosis and variability in treatment that is based more on the specialty of the provider than disease characteristics, according to a study published in the November issue of the Journal of the American Academy of Dermatology.

Weilan Johnson, M.D., from the Texas Health Presbyterian Hospital Dallas, and Heidi Jacobe, M.D., from the University of Texas Southwestern Medical Center, assessed the duration between morphea onset and diagnosis in a cohort of 224 patients. The specialty of the provider, initial evaluation, and therapy were also examined.

The researchers found that 63 percent of patients received a diagnosis more than six months after morphea onset. Most patients (83.5 percent) were diagnosed and treated by , with the more severe forms of morphea (linear and generalized) diagnosed and treated by rheumatologists. were the most commonly prescribed therapy (63 percent). Dermatologists mainly prescribed topical treatments or , even for those with linear and generalized morphea, while rheumatologists mainly prescribed systemic immunosuppressives and physical therapy.

"In summary, we identified several factors that impact the care of patients with morphea," the authors write. "These include delay in diagnosis and treatment, large variation in evaluation and therapy based on the specialty of the provider, and widespread use of evaluations and therapy with little evidence for their efficacy."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Ebola: Five questions about the killer virus

46 minutes ago

The highly contagious Ebola virus, which has killed more than 4,500 people in west Africa since December and has fueled global alarm, is among the most dangerous ever identified.

Ebola fear, monitoring eases for some in Dallas

56 minutes ago

The people closest to Ebola victim Thomas Eric Duncan are trying to resume their lives now that they have come out of a 21-day incubation period without developing symptoms of the disease.

Third UN employee dies from Ebola

1 hour ago

A UN staff member in Sierra Leone has died from Ebola, the third employee from the world organization to succumb to the deadly virus, the UN spokesman said Monday.

Canadian Ebola vaccine sent to WHO for testing

1 hour ago

The first batch of an experimental Ebola vaccine developed by Canadian scientists was sent to Switzerland on Monday for testing by the World Health Organization, officials said.

User comments